PLC is pleased to announce Neurelis is poised to initiate their pivotal clinical program for NRL-1

Jan

by Tracy Paul

20 January 2016 –PLC is pleased to announce Neurelis is poised to initiate their pivotal clinical program for NRL-1. PLC looks forward to their continued relationship with Neurelis as they support the clinical development and regulatory filings for NRL-1.

NEURELIS INITIATES PIVOTAL CLINICAL PROGRAM FOR NRL-1 IN THE TREATMENT OF ACUTE REPETITIVE SEIZURES

https://neurelis.com/neurelis-news/pivotal-clinical-program

Written by Tracy Paul

Translate »

Experience, Reliable, Effective

Congratulations to Indivior on the US FDA approval of their opioid overdose rescue medication for natural and synthetic opioids, OPVEE® (nalmefene) Nasal Spray

PLC commends ARS Pharmaceuticals for their recent favorable FDA Advisory Committee vote on the benefit-risk profile for neffy®

Written by Tracy Paul

Experience, Reliable, Effective

Congratulations to Indivior on the US FDA approval of their opioid overdose rescue medication for natural and synthetic opioids, OPVEE® (nalmefene) Nasal Spray

PLC commends ARS Pharmaceuticals for their recent favorable FDA Advisory Committee vote on the benefit-risk profile for neffy®

Written by Tracy Paul

Related Posts

Congratulations to Neurelis on their accepted presentations at the upcoming Annual Meeting of the American Academy of Neurolgy

PLC recognizes Neurelis’ recent announcement concerning first dosing of their first-in-human study to treat patients with cerebral cavernous malformation (CCM) with NRL-1049, a Rho kinase (ROCK) inhibitor

Congratulations to ARS Pharmaceuticals on their five accepted poster presentations at the 2022 American College of Allergy, Asthma and Immunology Annual Scientific Meeting.